The short version

Retatrutide is the weight-loss drug everyone's suddenly searching for — and the honest headline is two-sided. On one hand, it's the most powerful weight-loss molecule studied so far: in its Phase 2 trial, people lost an average of 24.2% of their body weight at 48 weeks on the top dose, and they hadn't even plateaued. On the other hand — and this is the part the hype skips — retatrutide is not FDA-approved. It's still in clinical trials. You cannot legitimately buy it, from any pharmacy or any telehealth program. The "retatrutide" sold online as a research peptide is an unregulated gray-market product with no verified dose, purity, or sterility, and the FDA has warned it hasn't been proven safe or effective for anyone. So this guide does two things honestly: it lays out the real science and timeline (what the trials actually show, and when it might realistically be approved), and it tells you the real risks of the gray market — plus what actually works right now while retatrutide finishes its trials. None of it is medical advice.

If you've landed here, you've probably seen the numbers that made retatrutide go viral: "30% weight loss," "beats Ozempic and Zepbound," "the strongest yet." Those claims aren't made up — they come from real trials run by Eli Lilly — but they're being passed around stripped of the one piece of context that matters most: this drug isn't available yet, and the version you can actually get your hands on is nothing like the one in the trials. That gap, between the promise in the research and the danger in the gray market, is the entire story, and almost no one tells both halves of it.

We're going to. This is an evidence-first explainer written to be the honest reference on retatrutide: what it is and why it's different from the drugs already on the market, exactly what the trial data shows (with the real percentages and their caveats), where it stands with the FDA and when approval might realistically come, and — most importantly — why buying "research peptide" retatrutide online is a genuinely risky idea, not a clever shortcut. Where a number comes from a trial or a regulator, we cite it. Where something is preliminary or uncertain, we say so plainly, because on a drug this new, false confidence is the dangerous thing.

One note on scope. This guide is about an investigational medication — a drug still being tested, not yet approved for sale. Nothing here is a recommendation to obtain or use retatrutide, and nothing here is medical advice. If you want effective weight-loss treatment today, the good news is that you don't have to wait for or gamble on retatrutide; FDA-approved options already deliver excellent results, and we'll point you to them. With that said, here's what retatrutide actually is.

What retatrutide actually is

Retatrutide (research code LY3437943) is an experimental once-weekly injection from Eli Lilly — the same company behind Mounjaro and Zepbound. What makes it notable is its mechanism. The GLP-1 drugs you already know work on gut hormones: Wegovy (semaglutide) targets one receptor, GLP-1; Zepbound (tirzepatide) targets two, GLP-1 and GIP. Retatrutide targets three — it's a "triple agonist" that activates the GLP-1, GIP, and glucagon receptors. That third target is the interesting one.

Here's why the glucagon receptor matters. GLP-1 and GIP mainly reduce how much you eat — less hunger, more fullness, slower stomach emptying. Adding glucagon-receptor activation does something different: it's thought to increase energy expenditure — roughly, how much energy your body burns — on top of reducing intake. So where semaglutide and tirzepatide primarily turn down the "calories in" side of the equation, retatrutide is designed to turn down intake and turn up output at the same time. Preclinical research and the Phase 2 trial (Jastreboff et al., NEJM 2023) describe exactly this triple mechanism, and it's the leading explanation for why its weight-loss numbers have come in higher than anything before it.

It's worth being precise about the "most powerful" framing, though, because it gets abused. Retatrutide's numbers look higher than semaglutide's or tirzepatide's — but almost every comparison you'll see is a cross-trial comparison, lining up retatrutide's result from one study against another drug's result from a different study with different people. That's genuinely unreliable (we explain why in our head-to-head guide). There has been no trial pitting retatrutide directly against tirzepatide or semaglutide in the same people, so "retatrutide beats Zepbound" is a reasonable hypothesis, not an established fact. What is established is that retatrutide's own trial numbers are, on their face, the largest averages the field has produced. Let's look at them.

The data: how much weight does retatrutide cause?

The strongest evidence we have is the Phase 2 obesity trial, published in the New England Journal of Medicine in 2023 (Jastreboff et al.). It randomized 338 adults with obesity to different doses of retatrutide or placebo for 48 weeks. This is peer-reviewed, placebo-controlled data — the kind worth taking seriously. Here's what it found.

GroupAvg. weight loss at 24 weeksAvg. weight loss at 48 weeks
Retatrutide 12 mg−17.5%−24.2%
Retatrutide 8 mg~−16%~−22%
Placebo−1.6%~−2%

Phase 2 trial data from NEJM 2023. The 12 mg group's 24.2% at 48 weeks is the headline result; lower-dose and intermediate figures are approximate as read from the dose-response curve.

Two things make that 24.2% remarkable. First, it's the highest average any weight-loss drug has posted in a trial of this kind — for comparison, tirzepatide's pivotal trial produced roughly 21% at its top dose, and semaglutide's roughly 15%. Second, and arguably more striking: at 48 weeks, participants had not yet plateaued — the weight was still coming off when the study ended. The investigators specifically noted that longer treatment might have produced even more loss. Most weight-loss drugs flatten out well before a year; retatrutide was still working.

Beyond the scale, the Phase 2 data showed improvements in things that track with metabolic health — blood sugar, blood pressure, and liver fat among them — which is consistent with how these drugs tend to behave and is being studied further. A separate Phase 2 study looked specifically at fatty liver disease with encouraging results.

Phase 3 — the bigger, confirmatory trials — is where things stand now. Through 2026, Lilly reported topline results from its large Phase 3 program (the TRIUMPH trials; see the registry entry for TRIUMPH-3 on ClinicalTrials.gov), with reported average weight loss at the highest doses in the mid-to-high-20% range over about 80 weeks, and the company said the data complete the package it needs to seek approval. Treat those Phase 3 figures as preliminary: as of this writing they come from the manufacturer's announcements, with the full, peer-reviewed results still to be published and presented at medical meetings. They point the same direction as Phase 2 — very large weight loss — but "announced by the sponsor" is a weaker standard of evidence than "published and peer-reviewed," and you should hold them a little more loosely until the papers are out.

The honest read on the numbers

Retatrutide's weight-loss data is genuinely the most impressive the field has produced — roughly a quarter of body weight in Phase 2, still trending down at a year. But "best numbers in trials" and "best choice for you right now" are different statements, because the drug isn't available, no trial has compared it head-to-head with today's approved drugs, and trial averages shrink in the real world. Impressive is not the same as attainable.

Is retatrutide FDA-approved? (No — here's exactly where it stands)

This is the single most important fact in this entire guide, and it's the one the viral posts leave out: retatrutide is not approved by the FDA for anything. It is an investigational drug — still in clinical trials. It is not sold by pharmacies, it is not prescribed by legitimate doctors or telehealth clinics, and it cannot legally be compounded. Any claim that you can get "real" retatrutide today is, by definition, describing something outside the legitimate, regulated supply chain.

Here's the realistic timeline, framed honestly. Retatrutide has completed its large Phase 3 trials, and Lilly has said it plans to submit its application to the FDA (a Biologics License Application) around early 2027. An FDA review of a submission like that typically takes on the order of a year, which would put a possible approval decision no earlier than late 2027 — and that's a best case that assumes a smooth review. Approval is never guaranteed until it happens.

StageStatus (late 2026)
Phase 2 (obesity)✓ Complete — published (NEJM 2023)
Phase 3 (TRIUMPH program)✓ Topline results reported by the sponsor
FDA application (BLA) filedPlanned ~early 2027 (not yet submitted)
FDA approval decisionNot before ~late 2027 at the earliest (estimate)
Available by prescriptionNo — investigational only

Timeline reflects the manufacturer's stated plans and standard FDA review timeframes as of late 2026; dates are estimates and subject to change. Nothing here is a promise that retatrutide will be approved or available on any schedule.

So if your plan was "get retatrutide instead of Zepbound" — the honest answer is that isn't a real option yet, and won't be for a while. The only tirzepatide-class drug you can legitimately get today is tirzepatide itself (Mounjaro/Zepbound), and the only semaglutide you can legitimately get is semaglutide (Ozempic/Wegovy). Which brings us to the part that's actively hurting people.

Can you buy retatrutide now? The gray market, honestly

Search "buy retatrutide" and you'll find websites selling vials of it — often cheaply, often labeled "for research purposes only" or "not for human consumption." That labeling is not a technicality or a wink; it's the loophole the whole gray market runs on. Selling a research chemical is treated differently from selling a drug for people to inject, so vendors slap the research label on and sell it anyway, knowing full well what buyers intend to do with it. This is the single most dangerous corner of the current weight-loss landscape, and it deserves a blunt warning.

Here's what you're actually buying when you buy gray-market retatrutide:

What the trials haveWhat a gray-market vial has
A precisely known doseUnknown dose — could be too little, too much, or none
Verified purity and identityNo verification — may be a different substance entirely, or counterfeit
Sterile, pharmaceutical-grade manufacturingNo sterility guarantee — contamination risk on an injectable
Medical supervision and dose titrationNone — you're dosing an experimental drug alone
Accountability if something goes wrongNone — an anonymous seller with no recourse

This isn't hypothetical hand-wringing. The FDA has stated that retatrutide has not been found safe and effective for any use, has warned specifically about products marketed "for research purposes" or "not for human consumption," and has acted against unauthorized sellers; its broader warnings about unapproved GLP-1 drugs used for weight loss apply directly here. Independent coverage and patient-safety groups have documented a growing black market in retatrutide, with reports of adverse events — and regulators have received reports of harm associated with alleged retatrutide products (unverified as to cause, but exactly the kind of signal you'd expect when people inject an unregulated experimental drug). Consumer-health references like GoodRx and Healthline reach the same conclusion: wait for approval; don't source it from the gray market.

The deeper problem is that with an injectable, the failure modes are serious. A contaminated vial can cause infection. A mislabeled concentration can cause a dangerous overdose — these are potent drugs, and the gray market has no quality control to catch an error. And because you're doing it without a clinician, there's no one adjusting your dose, watching for the warning signs these drugs carry, or helping if something goes wrong. The money you'd "save" versus an approved drug is nothing against those risks. The trial results are real; the vial on a research-chemical website is not the trial drug, and treating them as the same thing is the mistake that's hurting people.

If you take one thing from this guide

The retatrutide in the headlines (precise dose, sterile, supervised, ~24% weight loss) and the retatrutide for sale online right now (unknown dose, unverified, unsupervised, unregulated) are not the same product. The first isn't available yet. The second isn't worth the risk. There is no legitimate way to get trial-grade retatrutide today — and that's the honest answer, even though it's not the one the hype wants.

What the trials show about side effects

Even setting aside the gray-market problem, retatrutide is not a free lunch, and its trial safety profile is worth knowing. The most common side effects in the studies were gastrointestinal — nausea, diarrhea, vomiting, constipation — the same pattern seen across this whole drug class, and generally dose-related and worst during dose escalation. These are the same kinds of effects people manage on semaglutide and tirzepatide, covered in our GLP-1 side-effects guide.

Retatrutide also showed a signal worth flagging because of its extra mechanism: a dose-related increase in heart rate was observed in the trials. Effects on heart rate are something regulators look at carefully, and it's one of the things the larger Phase 3 program and the FDA review will scrutinize before any approval. There were also the expected cautions around blood sugar and other class effects. The point isn't that retatrutide looks unsafe in trials — its trial safety has broadly resembled the rest of the class — it's that a real drug has a real risk profile that needs real monitoring, which is precisely what you don't get injecting a gray-market vial on your own. The supervised trial setting is part of why those results looked as manageable as they did.

This is also why "it's basically a stronger Zepbound, so it must be fine" is faulty reasoning. A third mechanism means a third set of effects to understand, and that understanding is exactly what the trial-and-approval process exists to produce. Until it's done, the full real-world safety picture simply isn't in yet.

What actually works right now (while retatrutide finishes trials)

Here's the reframe that matters: you don't need to wait for retatrutide, and you definitely don't need to gamble on the gray market, to get excellent results. The drugs already approved and available are not a consolation prize. Tirzepatide — the Zepbound/Mounjaro molecule — produces roughly 21% average weight loss in trials, and semaglutide (Wegovy/Ozempic) roughly 15%. Those are life-changing numbers, available legitimately, today, with a prescriber watching your dose and your safety. Retatrutide's edge over them is real but incremental and unproven head-to-head — and "available now, supervised, and FDA-approved" beats "maybe a few points more, someday, if you survive the gray market."

The sensible play while retatrutide is still in trials is to start on a proven, approved GLP-1 through a legitimate program — one that gives you a real clinician, honest pricing, and proper titration — and let the field come to you. If retatrutide is approved down the line and it's right for you, switching between these drugs under medical guidance is routine. You lose nothing by treating your weight now with what works, and you avoid everything that can go wrong with an unregulated vial.

If you want to understand the approved options first, our guides on tirzepatide vs semaglutide and Wegovy vs Zepbound lay out the real differences, and our realistic results guide sets honest expectations. When you're ready to actually start, the programs below are our current top-rated picks for getting a legitimate, supervised GLP-1 — the right next step while retatrutide is still years from a pharmacy shelf.

9.8/10
embody
Best overall value
$49/moflat, locked-in — same at every dose

Compounded GLP-1 injections at a flat, locked-in $49/mo.

Visit embody Read our full review
9.6/10
Eden
Best for flat, predictable pricing
$99/moflat, same at every dose

Compounded GLP-1 at one flat price — $99 semaglutide, $129 tirzepatide, the same every month.

Visit Eden Read our full review

Our picks among online GLP-1 programs. Rankings and reviews are decided independently; we may earn a commission from some providers, which can affect placement but not our scores. How we make money · How we score.

Retatrutide: frequently asked questions

Is retatrutide FDA-approved?

No. As of late 2026, retatrutide is an investigational drug still in the approval process. Its large Phase 3 trials are complete and the manufacturer (Eli Lilly) has said it plans to file for FDA approval around early 2027, which — given typical review times — means a possible approval decision no earlier than late 2027, and only if the review goes smoothly. It is not currently available by prescription from any legitimate pharmacy or telehealth program.

How much weight do people lose on retatrutide?

In its peer-reviewed Phase 2 trial, adults on the 12 mg dose lost an average of 24.2% of their body weight at 48 weeks — the highest average any weight-loss drug has posted in a trial like this — and they hadn't plateaued yet. The manufacturer's 2026 Phase 3 topline reports point in the same direction (mid-to-high-20% range over ~80 weeks), though those full results are still to be peer-reviewed. Real-world results, once it's approved, would likely be somewhat lower than trial averages.

Can I buy retatrutide online right now?

You'll find websites selling it as a "research peptide" labeled "not for human consumption," but this is unregulated gray-market product, not the trial drug. It has no verified dose, purity, or sterility; the FDA has warned it hasn't been proven safe or effective and has acted against sellers; and there have been reports of harm associated with alleged retatrutide products. Injecting an unregulated experimental drug without medical supervision is a serious risk, not a shortcut. There is no legitimate way to obtain trial-grade retatrutide today.

Is retatrutide better than Zepbound or Wegovy?

Its trial numbers are higher on paper — roughly 24% versus about 21% for tirzepatide (Zepbound) and 15% for semaglutide (Wegovy) — but no trial has compared retatrutide directly against them in the same people, so "better" is an educated guess, not an established fact. And a drug that's unavailable can't be "better" for you in any practical sense right now. The approved drugs work extremely well and you can actually get them.

What makes retatrutide different from other GLP-1 drugs?

It's a "triple agonist" — it activates three receptors (GLP-1, GIP, and glucagon) instead of one or two. The extra glucagon-receptor target is thought to increase energy expenditure on top of reducing appetite, which is the leading explanation for its larger weight-loss numbers. More mechanisms also means more to understand about its full effects, which is part of what the trials are still establishing.

When will retatrutide be available?

Realistically not before late 2027 at the earliest, and that assumes the manufacturer files around early 2027 as planned and the FDA review goes smoothly — neither of which is guaranteed. Anyone telling you that you can get the real drug sooner is describing the gray market, not a legitimate source. The sensible move is to treat your weight now with an approved, supervised option rather than wait.

The bottom line

Retatrutide is genuinely exciting science — the strongest weight-loss results the field has produced, from a legitimate drugmaker, on track to seek FDA approval. It is also not available, and the "retatrutide" sold online today is an unregulated gray-market product that is not worth the risk to your health. The honest move isn't to chase it — it's to get effective, FDA-approved treatment now, under real medical supervision, and let retatrutide reach you through the front door if and when it's approved.

This article is general information about an investigational medication, not medical advice, and not an endorsement or recommendation to obtain or use retatrutide or any unapproved drug. Trial figures, timelines, and regulatory status described here are a late-2026 snapshot and will change — verify current status with the FDA and the manufacturer. Decisions about weight-loss treatment should be made with a licensed clinician.